Abstract
In this study, the protective efficacy of a novel recombinant BCG strain co-expressing Ag85B and Rv3425 against Mycobacterium tuberculosis H37Rv was evaluated in mice. This rBCG::Ag85B-Rv3425 strain could provide similar or even better protective efficacy against M. tuberculosis challenge compared with BCG, as shown by no weight loss, significantly reduced lung:body weight ratios and lung bacteria load only at early time of infection. The results suggest that rBCG::Ag85B-Rv3425 could be a potential tuberculosis vaccine candidate for further study.
Keywords:
Rv3425 protein; mycobacterium tuberculosis; recombinant BCG.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyltransferases / genetics
-
Acyltransferases / immunology*
-
Animals
-
Antigens, Bacterial / genetics
-
Antigens, Bacterial / immunology*
-
BCG Vaccine / administration & dosage
-
BCG Vaccine / genetics
-
BCG Vaccine / immunology*
-
Bacterial Load
-
Bacterial Proteins / genetics
-
Bacterial Proteins / immunology*
-
Body Weight
-
Disease Models, Animal
-
Female
-
Lung / microbiology
-
Lung / pathology
-
Mice
-
Mice, Inbred C57BL
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology
-
Tuberculosis, Pulmonary / immunology
-
Tuberculosis, Pulmonary / prevention & control*
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / immunology
Substances
-
Antigens, Bacterial
-
BCG Vaccine
-
Bacterial Proteins
-
Recombinant Fusion Proteins
-
Vaccines, Synthetic
-
Acyltransferases
-
antigen 85B, Mycobacterium tuberculosis